Comparing the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI in breast cancer recurrence: a systematic review and meta-analysis

Shiqing Liu, Yu Xie, Wei Ding, Xiaopeng Ma, Zhilin Li, Lei Zhang, Ya Zhang, Conghui AiFrontiers in Medicine 2025 · DOI

Abstract

[18F]FDG PET/CT and [18F]FDG PET/MRI exhibit comparable sensitivity and specificity in detecting breast cancer recurrence at both the lesion and patient levels. However, high heterogeneity warrants further head-to-head studies to strengthen the evidence and provide more comprehensive insights.

Introduction

Breast cancer remains a leading cause of mortality among women, with at least 35% of patients experiencing local or distant recurrence within a decade of initial treatment. Early and accurate detection is critical for survival, yet traditional imaging modalities—such as mammography, CT, and MRI—often struggle to distinguish between post-operative fibrosis and true tumor recurrence.

Molecular imaging using [18F]FDG, a glucose analog that highlights hypermetabolic cancer cells, has significantly advanced the field. However, a debate persists regarding whether the newer, more resource-intensive PET/MRI is superior to the established PET/CT. While PET/MRI offers enhanced soft-tissue contrast and lower radiation exposure, its relative diagnostic efficacy for recurrence has not been definitively established through large-scale meta-analysis until now.

Methods and Study Selection

This systematic review and meta-analysis were conducted following PRISMA-DTA guidelines. Researchers performed a comprehensive search of PubMed, Web of Science, and Embase for studies published through June 2025. The selection process identified 17 relevant studies involving a total of 1,450 patients.

Figure 1: Detailed screening and selection process for the included studies.

Data were analyzed at both the lesion level (individual suspicious spots) and the patient level (overall diagnosis). To ensure the reliability of the findings, the Quality Assessment for Studies of Diagnostic Accuracy-2 (QUADAS-2) tool was used to evaluate the risk of bias across four domains: patient selection, index test, reference standard, and flow/timing.

Figure 2: Quality assessment of the included studies using the QUADAS-2 tool, highlighting risks of bias and applicability concerns.

Results

The quantitative synthesis demonstrated high diagnostic performance across both modalities with no statistically significant differences in accuracy.

Lesion-Level Performance: * PET/CT: Sensitivity 0.97 | Specificity 0.79 * PET/MRI: Sensitivity 0.95 | Specificity 0.87 * Comparison: No significant difference (p=0.71 for sensitivity; p=0.66 for specificity).

Patient-Level Performance: * PET/CT: Sensitivity 0.93 | Specificity 0.87 * PET/MRI: Sensitivity 0.99 | Specificity 0.98 * Comparison: No significant difference, although PET/MRI showed a non-significant trend toward higher specificity (p=0.06).

These results suggest that diagnostic efficacy is largely driven by the [18F]FDG tracer itself. Because both modalities rely on the same metabolic signal to identify active tumors, the choice of anatomical "underlay" (CT vs. MRI) results in statistically similar outcomes for general recurrence detection.

Discussion and Clinical Implications

While diagnostic accuracy is comparable, the choice between PET/CT and PET/MRI involves practical trade-offs. PET/CT is faster, more cost-effective, and more widely available. Conversely, PET/MRI is ideal for younger patients or those requiring frequent scans due to its significantly lower radiation dose. Furthermore, MRI’s superior soft-tissue contrast may be slightly better at "ruling out" recurrence by identifying benign post-surgical changes that CT might flag as suspicious.

The study acknowledges several limitations, including a significant data imbalance (16 PET/CT studies vs. 4 PET/MRI studies) and high heterogeneity ($I^2$ up to 86.5%) likely due to varied imaging protocols. Future research should prioritize large-scale, prospective, head-to-head studies to confirm if the slight specificity advantages of PET/MRI hold up under rigorous standardized testing.

Summary updated

Abstract

[<sup>18</sup>F]FDG PET/CT and [<sup>18</sup>F]FDG PET/MRI exhibit comparable sensitivity and specificity in detecting breast cancer recurrence at both the lesion and patient levels. However, high heterogeneity warrants further head-to-head studies to strengthen the evidence and provide more comprehensive insights.
BibTeX
@inproceedings{liu2025comparing,
  author = {Shiqing Liu and Yu Xie and Wei Ding and Xiaopeng Ma and Zhilin Li and Lei Zhang and Ya Zhang and Conghui Ai},
  title = {{Comparing the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI in breast cancer recurrence: a systematic review and meta-analysis}},
  booktitle = {Frontiers in Medicine},
  year = {2025},
  doi = {10.3389/fmed.2025.1602415},
}
Figure